Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Immunotherapy. Found 57 abstracts

no pagination
Arora S, Velichinskii R, Lesh RW, Ali U, Kubiak M, Bansal P, Borghaei H, Edelman MJ, Boumber Y. Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. Advances in therapy. 2019 Aug 13;36(10):2638-78.   PMCID: PMC6778545
Bair SM, Strelec LE, Feldman TA, Ahmed G, Armand P, Shah NN, Singavi AN, Reddy N, Khan N, Andreadis C, Vu K, Huntington SF, Giri S, Ujjani C, Howlett C, Faheem M, Youngman MR, Nasta SD, Landsburg DJ, Schuster SJ, Svoboda J. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis. The oncologist. 2019 Jul;24(7):955-62.   PMCID: PMC6656463
Barta SK, Zain J, MacFarlane AW, Smith SM, Ruan J, Fung HC, Tan CR, Yang Y, Alpaugh RK, Dulaimi E, Ross EA, Campbell KS, Khan N, Siddharta R, Fowler NH, Fisher RI, Oki Y. Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma. Clinical lymphoma, myeloma & leukemia. 2019 Jun;19(6):356-364 e3.
Beck TN, Kudinov AE, Dulaimi E, Boumber Y. Case report: reinitiating pembrolizumab treatment after small bowel perforation. BMC cancer. 2019 Apr 24;19(1):379.   PMCID: PMC6482547
Ghatalia P, Gordetsky J, Kuo F, Dulaimi E, Cai KQ, Devarajan K, Bae S, Naik G, Chan TA, Uzzo R, Hakimi AA, Sonpavde G, Plimack E. Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma. Journal for immunotherapy of cancer. 2019 May 28;7(1):139.   PMCID: PMC6540413
Pederzoli F, Bandini M, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan UN, Theodore C, Rosenberg JE, Harshman LC, Bellmunt J, Galsky MD, Gallina A, Salonia A, Montorsi F, Necchi A. Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. Eur Urol. 2019 Oct;76(4):425-9.
Pignot G, Loriot Y, Kamat AM, Shariat SF, Plimack ER. Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies. European urology oncology. 2019 Jul;2(4):355-64.
Churilla TM, Weiss SE. Emerging Trends in the Management of Brain Metastases from Non-small Cell Lung Cancer. Current oncology reports. 2018 May 07;20(7):54.   PMCID: Review
Gerson JN, Ramamurthy C, Borghaei H. Managing adverse effects of immunotherapy. Clinical advances in hematology & oncology : H&O. 2018 May;16(5):364-74.   PMCID: Review
Godwin JL, Hoffman-Censits J, Plimack E. Recent developments in the treatment of advanced bladder cancer. Urol Oncol. 2018 Mar;36(3):109-14.   PMCID: Review
Marty Pyke R, Thompson WK, Salem RM, Font-Burgada J, Zanetti M, Carter H. Evolutionary Pressure against MHC Class II Binding Cancer Mutations. Cell. 2018 Oct 04;175(2):416-428e13.   PMCID: PMC6482006
Tripathi A, Plimack ER. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions. Current urology reports. 2018 Nov 07;19(12):109.
Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer. 2017 Apr;123(7):1259-71.   PMCID: PMC5705038
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, Decamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network. 2017 Apr;15(4):504-35.
Ghatalia P, Zibelman M, Geynisman DM, Plimack ER. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma. Current treatment options in oncology. 2017 Jan;18(1):7.   PMCID: Review
Judd J, Zibelman M, Handorf E, O'Neill J, Ramamurthy C, Bentota S, Doyle J, Uzzo RG, Bauman J, Borghaei H, Plimack ER, Mehra R, Geynisman DM. Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors. The oncologist. 2017 Jun 26;22(10):1232-7.   PMCID: PMC5634771
Merza H, Bilusic M. Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions. Current oncology reports. 2017 Apr;19(4):27.
Merza H, Bilusic M. Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions. Current oncology reports. 2017 Apr;19(4):27.   PMCID: Review
Ramamurthy C, Godwin JL, Borghaei H. Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?. Current treatment options in oncology. 2017 Jun;18(6):33.   PMCID: Review
Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RH, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017 Sep 07;170(6):1109-1119e10.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Immunotherapy

Immunotherapy methods Targeted therapy genetics etiology Immune checkpoint blockade adverse effects Combined Modality Therapy Checkpoint inhibitors immunology therapy Clinical Trials as Topic Pembrolizumab drug therapy Biomarkers Pd-1 Renal cell carcinoma diagnosis Urothelial carcinoma Antineoplastic Agents administration & dosage Non-small cell lung cancer Molecular Targeted Therapy Monoclonal Antibodies-Humanized immunotherapy Treatment Outcome Disease Management Immune-related adverse events Programmed Cell Death 1 Receptor Bladder cancer Tyrosine kinase inhibitors article PD-1 inhibitor Monoclonal Antibodies antagonists & inhibitors Kidney cancer therapeutic use Tumor Microenvironment cancer tumor evolution Hepatitis biomarkers Angioimmunoblastic lymphoma Recurrence-free survival Immunologic Factors Lung Neoplasms Mutation Peripheral T cell lymphoma Cancer checkpoint inhibitors Melanoma Programmed death-1 Age Factors CD4-Positive T-Lymphocytes Toxicity Mhc-ii Chemotherapy head and neck cancer CD8-Positive T-Lymphocytes Nivolumab pathology Adjuvant chemotherapy mortality Cytotoxic T-lymphocyte antigen 4 (CTLA-4) CTLA-4 Antigen Non-Small-Cell Lung Carcinoma Patient Selection B7-H1 Antigen Immune checkpoints inhibitors Hematologic Neoplasms Cytotoxic T-lymphocyte associated protein 4 Immune checkpoint inhibitors Molecular Evolution Bowel perforation Histocompatibility Antigens Class I oncolytic viruses Dermatitis Real-world Neoplastic Gene Expression Regulation Radiotherapy Nomogram Kidney Neoplasms Immune cell immune editing Prognosis human papillomavirus talimogene laherparepvec Local treatment United States Tumor infiltrating lymphocytes National Cancer Institute (US) Histocompatibility Antigens Class II Programmed death 1 (PD-1) Colitis Herpesviridae Srt Ipilimumab Neoadjuvant Stereotactic radiation therapy Neoplasm Antigens tumor interferon gamma Vegf cytotixic Ctla4 Adjuvant melanoma T cells Hodgkin lymphoma T lymphocytes immunity Recurrence Neoplasm Staging Pd-l1 driver mutations Brain metastases Localized prevention & control oncolytic immunotherapy Platinum ineligible Stereotactic radiosurgery Wbrt Whole brain radiotherapy Mismatch repair deficiency (MMR) Checkpoint inhibitor Tumor mutation burden (TMB) Programmed cell death 1 inhibitors Pneumonia Programmed death 1 Srs Neoplasm Metastasis Muscle-invasive bladder cancer clinical trials anti-PD-1 DNA damage response (DDR) Neoplasms Head and Neck Neoplasms Oncolytic Virotherapy Renal Cell Carcinoma Clinical trials pembrolizumab
Last updated on Monday, November 04, 2019